First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)
Authors:
- J. SastreJSJ. Sastre
- E. ArandaEAE. Aranda
- C. GrávalosCGC. Grávalos
- B. MassutíBMB. Massutí
- M. Varella-GarciaMVM. Varella-Garcia
- F. RiveraFRF. Rivera
- G. SolerGSG. Soler
- A. CarratoACA. Carrato
- J.L. ManzanoJMJ.L. Manzano
- E. Díaz-RubioEDE. Díaz-Rubio
- M. HidalgoMHM. Hidalgo
- 1 January 2011
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 77 (1) , 78-84
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and ChemotherapyJournal of Clinical Oncology, 2008
- Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patientsBritish Journal of Cancer, 2008
- First-line single-agent cetuximab in patients with advanced colorectal cancerAnnals of Oncology, 2007
- Cetuximab for the Treatment of Colorectal CancerNew England Journal of Medicine, 2007
- Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal CancerJournal of Clinical Oncology, 2007
- Irinotecan in Combination With Fluorouracil in a 48-Hour Continuous Infusion As First-Line Chemotherapy for Elderly Patients With Metastatic Colorectal Cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors StudyJournal of Clinical Oncology, 2005
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimenEuropean Journal of Cancer, 2002
- Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment TrialsNew England Journal of Medicine, 1999
- Uracil and tegafur modulated with leucovorinCancer, 1997